Past exam of the biochemistry course of the University of Cambridge / 2024 / Paper 5 / Section 2 / g / Solution

Sequestration of assembly-competent G-actin explains both inhibition of polymer formation and loss of pre-existing cellular structures. In a simple model, free actin monomer $G$ binds drug $D$ to form an assembly-incompetent complex $GD$. At a actin filament end the net addition rate is $v=k_{+}[G]-k_{-}$, so lowering free $[G]$ reduces elongation and can drive net shortening below the relevant actin critical concentration $C_c=k_{-}/k_{+}$. Formation of new nuclei is also strongly reduced when free actin monomer is depleted. Existing actin filaments can consequently disappear through ordinary turnover even though ToxB never binds them.

Binding could instead or additionally alter the actin monomer conformation or nucleotide state needed for productive assembly. The resistant mutant supports an interaction with actin, but resistance could reflect reduced drug affinity, an allosteric change or altered assembly properties. The available endpoints do not uniquely distinguish these possibilities. In particular, they provide no positive evidence for direct actin filament severing or actin filament capping by ToxB. A real example of actin-monomer sequestration and resistant-actin genetics is latrunculin A; this is an analogy, not a chemical identification of ToxB.^[ref]